Adverse-Event Profile of Crataegus Spp.
- 179 Downloads
Crataegus spp. (hawthorn) monopreparations are predominantly used for treating congestive heart failure. The effectiveness of hawthorn preparations (flowers with leaves; berries) is documented in a number of clinical studies, reviews and meta-analyses. The aim of this article is to assess the safety data of all available human studies on hawthorn monopreparations.
Systematic searches were conducted on MEDLINE, EMBASE, AMED, The Cochrane Library, the UK National Research Register and the US ClinicalTrials.gov (up to January 2005). Data were requested from the spontaneous reporting scheme of the WHO. Hand searches were also conducted in a sample of relevant medical journals, conference proceedings, reference lists of identified articles and our own files. Eight manufacturers of hawthorn-containing preparations were contacted and asked to supply any information on adverse events or drug interactions. Data from all clinical studies and reports were assessed. Only human studies on monopreparations were included. Data from hawthorn-containing combination preparations and homeopathic preparations were excluded. All studies were read and evaluated by one reviewer and independently verified by at least one additional reviewer.
Twenty-nine clinical studies were identified, of which 24 met our inclusion criteria. A total of 7311 patients were enrolled, and data from 5577 patients were available for analysis. The daily dose and duration of treatment with hawthorn monopreparations ranged from 160 to 1800mg and from 3 to 24 weeks, respectively. The extracts most used in the clinical trials were WS 1442 (extract of hawthorn standardised to 18.75% oligomeric procyanidins) and LI 132 (extract of hawthorn standardised to 2.25% flavonoids). Overall, 166 adverse events were reported. Most of these adverse events were, in general, mild to moderate; eight severe adverse events have been reported with the LI 132 extract. The most frequent adverse events were dizziness/vertigo (n = 15), gastrointestinal complaints (n = 24), headache (n = 9), migraine (n = 8) and palpitation (n = 11). The WHO spontaneous reporting scheme received 18 case reports. In the identified trials, the most frequent adverse events were dizziness (n = 6), nausea (n = 5), fall (n = 2), gastrointestinal haemorrhage (n = 2), circulation failure (n = 2) and erythematous rash (n = 2). There were no reports of drug interactions.
In conclusion, all data reviewed in this article seem to indicate that hawthorn is well tolerated even if some severe adverse events were reported; this suggests that further studies are needed to better assess the safety of hawthorn-containing preparations. Moreover, the unsupervised use of this drug can be associated with problems, especially if given with concomitant medications.
KeywordsChronic Heart Failure Randomise Clinical Trial Frequent Adverse Event International Drug Monitoring Oligomeric Proanthocyanidins
The authors wish to thank Dr Antonella Di Sotto, Department of Pharmacology of Natural Substance and General Physiology, University of Rome, ‘La Sapienza’, Rome, Italy, for her support.
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
- 3.Williamson EM. British herbal pharmacopoeia, 1983. Bournemouth: British Herbal Medicine Association (BHMA) Publications, 2003Google Scholar
- 4.Weiss RF, Fintelmann V. Herbal medicine. New York: Thieme Stuttgart, 2000Google Scholar
- 5.Newall A, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: The Pharmaceutical Press, 1996Google Scholar
- 6.Blumenthal M. The ABC clinical guide to herbs. Austin (TX): American Botanical Council, 2003Google Scholar
- 7.Blumenthal M, Busse WR, Goldberg A. The complete Commission E monographs. Austin (TX): American Botanical Council, 2000Google Scholar
- 9.Weiss RF, Fintelmann V. Herbal medicine. New York: Thieme Stuttgart, 2000Google Scholar
- 11.Societàl Italiana di Fitoterapia, Organizzazione Mondiale della Sanità (OMS). Monografie di piante medicinali. Vol. 2. Abbiategrasso (Milan), Italy: Le Nuove Scritture, 2004Google Scholar
- 13.Reynolds JEJ, editor. Hawthorne. Martindale: the extra pharmacopoeia. London: The Royal Pharmaceutical Society of Great Britain, Pharmaceutical Press, 1996: 1600Google Scholar
- 15.O’Connolly M, Bernhoft G, Bartsch G. Behandlung alterer, multimorbider Patienten mit stenokardischen Beschwerden: Eine placebokontrollierte crossover-Doppelblindstudie mit Crataegutt® novo. Therapiewoche 1987; 37: 3587–600Google Scholar
- 16.O’Connolly M, Jansen W, Bernhôft G, et al. Treatment of decreasing cardiac performance (NYHA stages I to II) in advanced age with standardized crataegus extract. Fortschr Med 1986; 42: 805–8Google Scholar
- 17.Hanak T, Brûckel MH. Behandlung von leichten stabilen Formen der Angina pectoris mit Crataegutt novo. Therapiewoche 1983; 33: 4331–3Google Scholar
- 19.Eichstâdt H, Stôrk T, Môckel M. Wirksamkeit und Vertrâglichkeit von Crataegus-Extrakt WS®1442 bei herzinsuffizienten Patienten mit eingeschrankter linksventrikulârer Funktion. Perfusion 2001; 14: 212–7Google Scholar
- 23.Staiger J, Kuhn H, Spâth J. Zur kardialen Wirksamkeit von low-dose digitoxin (0.07 mg) and crataegus. Med Welt 1987; 38: 1023–8Google Scholar
- 24.Eichstâdt H, Bâder M, Danne O. Crataegus-Extrakt hilft dem Patienten mit NYHA II-Herzinsuffizienz. Therapiewoche 1989; 39: 3288–96Google Scholar
- 25.Weikl A, Noh HS. Der Einfluss von Crataegus bei globaler Herzinsuffizienz. Herz Gefâsse 1992; 12: 6–24Google Scholar
- 28.Alexander A. Klinische Wirkung des Crataegus Extraktes LI132 bei der Therapie der Herzinsuffizienz im Stadium II der New York Heart Association. Eine randomisierte, plazebokontrollierte Doppelblindstudie an N = 73 Patienten [doctoral thesis; online]. Available from URL: http://edoc.hu-berlin.de/docviews/abstract.php?lang=ger&id=10095 [Accessed 2006 Jan 27]Google Scholar
- 29.Bôadigheimer K, Chasa D. Effectiveness of hawthorn extract at a dosage of 3 × 100mg per day: multicentre double-blind trial with 85 NYHA stage II heart failure patients. Mûanch Med Wochenschr 1994; 136: S7–S11Google Scholar
- 31.Tauchert M, Ploch M, Hubner WD. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Mûanch Med Wochenschr 1994; 136: S27–33Google Scholar
- 32.Fischer K, Jung F, Koscielny J, et al. Crataegus-extract vs methyldidoxin. Mûanch Med Wochenschr 1994; 136: S35–8Google Scholar
- 33.Fôrster A, Fôrster K, Bûhring M, et al. Crataegus bei mâβiger reduzierter linksventrikulârer Auswurffraktion. Mûanch Med Wochenschr 1994; 136: S21–6Google Scholar
- 34.Schmidt U, Albrecht M, Podzuweit H. High dosed therapy with crataegus extract in patients suffering from heart failure NYHA stage I and II. Z Phytother 1998; 19: 22–30Google Scholar
- 39.Ernst E, Pittler MH, Stevinson C, et al. The desktop guide to complementary and alternative medicine: an evidence based approach. Edinburgh: Mosby, 2001Google Scholar
- 40.Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). Clin Pharmacol 2003; 43: 637–42Google Scholar
- 41.Mills S, Bone K. The essential guide to herbal safety. Edinburgh: Elsevier Churchill Livingstone, 2005Google Scholar